Cargando…
Drugs for solid cancer: the productivity crisis prompts a rethink
Despite remarkable progress in cancer-drug discovery, the delivery of novel, safe, and sustainably effective products to the clinic has stalled. Using Src as a model, we examine key steps in drug development. The preclinical evidence on the relationship between Src and solid cancer is in sharp contr...
Autores principales: | Rösel, Daniel, Brábek, Jan, Veselý, Pavel, Fernandes, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699349/ https://www.ncbi.nlm.nih.gov/pubmed/23836990 http://dx.doi.org/10.2147/OTT.S45177 |
Ejemplares similares
-
Pragmatic medicine in solid cancer: a translational alternative to precision medicine
por: Brábek, Jan, et al.
Publicado: (2016) -
Solid cancer: the new tumour spread endpoint opens novel opportunities
por: Fernandes, Michael, et al.
Publicado: (2019) -
The role of the tissue microenvironment in the regulation of cancer cell motility and invasion
por: Brábek, Jan, et al.
Publicado: (2010) -
Are We Ready for Migrastatics?
por: Solomon, Jonathan, et al.
Publicado: (2021) -
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
por: Gandalovičová, Aneta, et al.
Publicado: (2017)